SFEBES2013 Poster Presentations Obesity, diabetes, metabolism and cardiovascular (67 abstracts)
Acute effects of co-infusion of peptide YY (3–36) and glucagon-like peptide-1 on insulin secretion and insulin sensitivity
Tricia Tan 1 , Victoria Salem 1 , Rachel Troke 1 , Akila De Silva 1 , Ali Alsafi 1 , Shivani Misra 1 , Kevin Baynes 1 , Mohammed Ghatei 1 , James Minnion 1 , Ben Field 1 , Ian Godsland 2 & Stephen R Bloom 1
1Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Hospital, London, UK; 2Division of Endocrinology and Metabolic Medicine, Department of Medicine, Imperial College London, St Mary’s Hospital, London, UK.
The amelioration of type 2 diabetes and sustained weight loss after bariatric surgery are thought to be due to elevated circulating levels of the gut hormones peptide YY3–36 (PYY3–36) and glucagon-like peptide-1 (GLP-1). GLP-1 augments the insulin response to an oral glucose load. PYY3–36 has appetite-inhibitory effects and contributes to longer-term weight loss. Rodent studies provide conflicting data regarding the effects of PYY on glucose homeostasis: PYY may enhance insulin-mediated glucose disposal, but in vitro evidence suggests that the activation of Y1-receptors (which mediate the effects of PYY on pancreatic islet cells) may inhibit insulin release. No study to date has examined the effects of PYY on glucose homeostasis, either alone or in combination with GLP-1, in humans.
Hypothesis: GLP-1 will exert a beneficial effect on glucose homeostasis in healthy, overweight human volunteers, and co-administration with PYY3–36 will not attenuate this response.
Methods: Fourteen overweight healthy volunteers were studied in a single-blinded crossover fashion. They were randomised to receive four infusions: i) vehicle; ii) GLP-1 at 0.2 pmol/kg per min; iii) PYY3–36 at 0.15 pmol/kg per min; and iv) co-infusion of GLP-1 plus PYY3–36 at the above doses. During each intervention, a frequently sampled intravenous glucose tolerance test was performed to assess acute insulin response to glucose (AIRg), and insulin sensitivity (Si), using minimal modeling.
Results: AIRg was significantly increased by infusion of GLP-1 alone, compared to all other interventions (P<0.05). No acute effect on Si was noted with any of the interventions. The disposition index (AIRg×Si) was significantly greater following administration of GLP-1 alone than with any other intervention (P<0.05).
Conclusion: GLP-1 infusion increases the AIRg in healthy, overweight humans. In contrast, PYY infusion had no effect on AIRg and neither hormone, alone or in combination, was shown to enhance Si in the acute setting.
Declaration of funding: R Troke was supported by the Medical Research Council. The Department is funded by an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7-HEALTH-2009-241592 EurOCHIP grant and funding from the NIHR Biomedical Research Centre Funding Scheme.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more